Jorge R. Taborga Sells 2,068 Shares of Omnicell Inc. (OMCL) Stock
Omnicell Inc. (NASDAQ:OMCL) VP Jorge R. Taborga sold 2,068 shares of the stock in a transaction on Friday, November 18th. The shares were sold at an average price of $33.66, for a total transaction of $69,608.88. Following the transaction, the vice president now owns 47,223 shares in the company, valued at $1,589,526.18. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Shares of Omnicell Inc. (NASDAQ:OMCL) opened at 34.90 on Tuesday. The company has a market capitalization of $1.27 billion, a P/E ratio of 160.09 and a beta of 0.65. Omnicell Inc. has a 12 month low of $25.06 and a 12 month high of $40.50. The company has a 50-day moving average of $34.46 and a 200 day moving average of $35.22.
Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, October 27th. The company reported $0.40 EPS for the quarter, missing the Zacks’ consensus estimate of $0.41 by $0.01. Omnicell had a net margin of 1.24% and a return on equity of 10.74%. The firm earned $179.40 million during the quarter, compared to the consensus estimate of $179.75 million. During the same period in the prior year, the business earned $0.36 EPS. The company’s revenue for the quarter was up 43.3% compared to the same quarter last year. Analysts forecast that Omnicell Inc. will post $1.55 EPS for the current year.
Several institutional investors have recently added to or reduced their stakes in OMCL. Fisher Asset Management LLC raised its position in shares of Omnicell by 1.0% in the second quarter. Fisher Asset Management LLC now owns 536,152 shares of the company’s stock worth $19,452,000 after buying an additional 5,152 shares during the period. Henderson Group PLC raised its position in shares of Omnicell by 57.6% in the second quarter. Henderson Group PLC now owns 399,565 shares of the company’s stock worth $13,677,000 after buying an additional 145,997 shares during the period. PineBridge Investments L.P. raised its position in shares of Omnicell by 4.0% in the second quarter. PineBridge Investments L.P. now owns 4,555 shares of the company’s stock worth $156,000 after buying an additional 177 shares during the period. Goldman Sachs Group Inc. raised its position in shares of Omnicell by 62.9% in the first quarter. Goldman Sachs Group Inc. now owns 93,228 shares of the company’s stock worth $2,598,000 after buying an additional 36,015 shares during the period. Finally, First Trust Advisors LP bought a new position in shares of Omnicell during the second quarter worth about $747,000. 94.56% of the stock is currently owned by institutional investors.
A number of research analysts have commented on OMCL shares. Sidoti downgraded shares of Omnicell from a “buy” rating to a “neutral” rating and set a $43.00 price objective on the stock. in a research note on Thursday, September 8th. Oppenheimer Holdings Inc. set a $46.00 price objective on shares of Omnicell and gave the company a “buy” rating in a research note on Thursday, October 27th. Zacks Investment Research downgraded shares of Omnicell from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 3rd. FBR & Co raised their price target on shares of Omnicell from $40.00 to $41.00 and gave the stock an “outperform” rating in a research report on Friday, July 29th. Finally, TheStreet downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Friday, November 11th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $39.43.
Omnicell Company Profile
Omnicell, Inc (Omnicell) is a provider of automation and business information solutions designed to enable healthcare systems to streamline the medication administration process and manage medical supplies for increased operational efficiency and enhanced patient safety. The Company operates through two operating segments: Automation and Analytics, and Medication Adherence.
Receive News & Stock Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related stocks with our FREE daily email newsletter.